Jump to content

Drilldown: Medicines

Pharmacopedia is being built in public. Pages may be incomplete.About this site

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Classic Psychedelic

or Opioid

or [[:Category:Anti-inflammatories|Anti-inflammatory]]

Use the filters below to narrow your results.

Other values:

5-HT2A agonist (26) · Potent mu-opioid receptor agonist (6) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Mu-opioid receptor agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · None (2) · Contains LSA (2) · Contains mescaline (2)

Other values:

None (99) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000BBC-QINU`"', '"`UNIQ--vote-00000BBD-QINU`"' (1) · '"`UNIQ--vote-00000C6D-QINU`"', '"`UNIQ--vote-00000C6E-QINU`"', '"`UNIQ--vote-00000C6F-QINU`"', '"`UNIQ--vote-00000C70-QINU`"', '"`UNIQ--vote-00000C71-QINU`"' (1)

None (99) · Active UC: Lialda 2.4-4.8 g PO once daily, Apriso 1.5 g PO once daily; maintenance 1.2-2.4 g/d; rectal Rowasa enema 4 g HS for distal disease; Canasa 1 g suppository HS for proctitis (1) · Acute gout: 1.2 mg PO at first symptom, then 0.6 mg 1 hour later (total 1.8 mg in 1 hour, the FDA-revised regimen); prophylaxis 0.6 mg PO daily or BID; FMF 1-2 mg/d; pericarditis 0.5-0.6 mg BID for 3 months; Lodoco 0.5 mg PO daily for CV risk reduction (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (99) · 0.6 mg tablets; 0.6 mg/5 mL solution; 0.5 mg tablets (Lodoco) (1) · Multiple non-bioequivalent oral formulations (pH-, time-, and moisture-dependent release); rectal enema 4 g/60 mL; 1 g rectal suppository (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (99) · 1.8 mg in any 1-hour period (acute gout); 1.2 mg/d (prophylaxis with renal/hepatic impairment); much lower with strong CYP3A4 or P-gp inhibitors (1) · 360 mg/day (1) · Formulation-specific; ~4.8 g/d typical maximum oral (1)

None (98) · Oral (2) · Oral (IV form withdrawn US 2009 due to fatal toxicity reports) (1) · PO (only formulation marketed in the US). (1) · rectal (1)

None (98) · 30–60 min (PO) (1) · 30–60 minutes (1) · Anti-inflammatory effect within 24 hours of gout flare onset; loses effectiveness if delayed (1) · Symptomatic improvement 2-4 weeks (1)

None (98) · 24 hours (most ER formulations) (1) · 4–6 hours (1) · 8–12 hours (1) · Hours per dose (1)

None (98) · 2.5–3 hours (1) · 3–5 hours (1) · ~27-31 hours; markedly prolonged in renal/hepatic impairment and with CYP3A4 or P-gp inhibitors'"`UNIQ--ref-00000C72-QINU`"' (1) · ~5-10 hours (5-ASA)'"`UNIQ--ref-00000BBE-QINU`"' (1)

None (98) · 70–90% (oral) (1) · Highly formulation-dependent; the goal is colonic delivery with minimal systemic exposure'"`UNIQ--ref-00000BBF-QINU`"' (1) · ~45% (oral)'"`UNIQ--ref-00000C73-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (98) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Generally considered safe at standard doses; benefits typically outweigh in active IBD.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Not established (1) · Used in FMF in pregnancy; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (98) · Schedule I (United States) (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (2)

Showing below up to 102 results in range #1 to #102.

1

2

4

5

7

7-Hydroxymitragynine

A

B

C

D

E

F

Fentanyl

H

K

Kratom

L

Levorphanol

M

N

Nalbuphine

O

P

R

Remifentanil

S

T

U

U-47700

Y

Yopo

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"